Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03128879 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03128879 · ClinicalTrials.gov record · last posted 2026-08-10

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Name: Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL — clinical trial record (NCT03128879)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorM.D. Anderson Cancer Center

Started2017-06-16

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy. The study will estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable CLL after receiving ibrutinib or acalabrutinib for at least 12 months and who have high risk CLL.

Protocol amendment history 2 changes detected by DataLookout

2026-08-11

Enrollment closed, study ongoing

2026-08-11

Enrollment reduced: 90 → 59 participants

Trial Details

NCT Number	NCT03128879
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Chronic Lymphocytic Leukemia
Enrollment	59 participants
Start Date	2017-06-16
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10